Imaging of Advanced Medullary Thyroid Carcinoma with the CCK-2 Receptor Agonist 177Lu-PP-F11N – Preliminary Proof of the Principle within the “Lumed” Study

#2014

Introduction: Despite the introduction of new molecular targeted therapies, there is still an unmet need for an effective systemic therapy for advanced medullary thyroid carcinoma (MTC). Targeting the cholecystokinine-2 (CCK-2) receptor with radiolabeled gastrin analogues is a potential approach for radionuclide therapy of MTC.

Aim(s): The aim of this study is the feasibility testing of targeting CCK-2 receptors with the novel 177Lu-labelled gastrin analogue PP-F11N in six patients with advanced MTC. (ClinicalTrials.gov: NCT02088645).

Materials and methods: Six patients fulfilling the inclusion criteria (advanced MTC, Calcitonin > 100 pg/ml and/or doubling time < 24 months) were included in the study. All of them received two injections of 1 GBq 177Lu-PP-F11N with 4 weeks interval. Planar scintigraphy and SPECT/CT scans were performed at several time points post-injection. Several vital parameters were measured.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Rottenburger C, Nicolas G, McDougall L, Kaul F, Christ E,

Keywords: Medullary thyroid carcinoma, cholecystokinine-2 receptor, radionuclide therapy, theranostics,